GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (OTCPK:ATBPF) » Definitions » Tariff Resilience Score

ATBPF (Antibe Therapeutics) Tariff Resilience Score : 0/10 (As of Jul. 15, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Antibe Therapeutics Tariff Resilience Score?

Antibe Therapeutics has the Tariff Resilience Score of 0, which implies that the company might have .

Antibe Therapeutics has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Antibe Therapeutics might have .

Antibe Therapeutics  (OTCPK:ATBPF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Antibe Therapeutics Tariff Resilience Score Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's Tariff Resilience Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Antibe Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (OTCPK:ATBPF) » Definitions » Tariff Resilience Score
Comparable Companies
XCNQ:ACOG XCNQ:GLAB TSXV:TTI TSX:TH TSXV:GSD TSX:MBX TSX:APS TSXV:CZO TSXV:COV TSXV:MSCL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2
Website
https://www.antibethera.com
Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.